Safety and Efficacy of Ponatinib in Patients with Chronic Myeloid Leukemia with Resistant or Intolerant Chronic Phase, Accelerated Phase or Blast Phase and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with T315I Mutation
Latest Information Update: 01 Dec 2024
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms OITI
Most Recent Events
- 25 Nov 2024 According to an Incyte Corporation media release, data from this study will be presented t the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego.
- 15 Jun 2023 Results (n=120) assessing the treatment patterns and outcomes, including safety and efficacy of ponatinib in chronic myeloid leukaemia patients, presented at the 28th Congress of the European Haematology Association.
- 14 Dec 2021 Results (n=119) assessing the treatment patterns and outcomes, including safety and efficacy, in patients with CML treated in Italy since the approval of ponatinib, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.